Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-11-18 5:06 pm Purchase |
2022-11-08 | 13D | ARS Pharmaceuticals, Inc. SPRY |
Flynn James E | 11,077,927 11.810% |
11,077,927 (New Position) |
Filing History |
| 2022-11-18 4:14 pm Purchase |
2022-11-08 | 13G | Rain Enhancement Technologies Holdco Inc RAIN |
Flynn James E | 2,796,261 9.990% |
2,796,261 (New Position) |
Filing History |
| 2022-11-17 4:38 pm Purchase |
2022-11-16 | 13G | Brookdale Senior Living Inc. BKD |
Flynn James E | 12,216,561 6.540% |
7,941,753 (+185.78%) |
Filing History |
| 2022-11-16 4:47 pm Purchase |
2022-11-07 | 13G | Abeona Therapeutics Inc. ABEO |
Flynn James E | 1,739,130 5.060% |
1,739,130 (New Position) |
Filing History |
| 2022-11-14 4:45 pm Purchase |
2022-11-04 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 6,060,491 5.820% |
6,060,491 (New Position) |
Filing History |
| 2022-11-14 4:44 pm Purchase |
2022-11-02 | 13G | Frazier Lifesciences Acquisition Corporation FLAC |
Flynn James E | 2,572,986 17.340% |
2,572,986 (New Position) |
Filing History |
| 2022-11-14 4:42 pm Purchase |
2022-11-03 | 13G | Nuvalent, Inc. NUVL |
Flynn James E | 25,466,889 39.240% |
690,611 (+2.79%) |
Filing History |
| 2022-10-14 4:51 pm Purchase |
2022-10-10 | 13G | Enhabit, Inc. EHAB |
Flynn James E | 2,846,000 5.740% |
2,846,000 (New Position) |
Filing History |
| 2022-10-04 4:32 pm Purchase |
2022-10-03 | 13G | IVERIC bio, Inc. ISEE |
Flynn James E | 6,601,000 5.590% |
1,839,862 (+38.64%) |
Filing History |
| 2022-09-30 3:29 pm Purchase |
2022-09-20 | 13G | Merus N.V. MRUS |
Flynn James E | 2,521,553 5.500% |
2,521,553 (New Position) |
Filing History |
| 2022-09-23 5:15 pm Purchase |
2022-09-22 | 13G | Phathom Pharmaceuticals, Inc. PHAT |
Flynn James E | 2,414,897 5.810% |
2,414,897 (New Position) |
Filing History |
| 2022-09-16 5:19 pm Purchase |
2022-09-16 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 16,963,029 42.450% |
11,126,786 (+190.65%) |
Filing History |
| 2022-09-12 5:23 pm Sale |
2022-09-08 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
Flynn James E | 2,032,335 5.530% |
-1,250,577 (-38.09%) |
Filing History |
| 2022-08-17 1:11 pm Purchase |
2022-08-17 | 13G | GeneDx Holdings Corp. WGS |
Flynn James E | 571,166 4.950% |
147,929 (+34.95%) |
Filing History |
| 2022-08-16 5:20 pm Sale |
2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN |
Flynn James E | 1,860,000 4.940% |
-485,959 (-20.71%) |
Filing History |
| 2022-08-16 5:19 pm Purchase |
2022-08-16 | 13G | Vigil Neuroscience, Inc. VIGL |
Flynn James E | 2,054,794 5.780% |
2,054,794 (New Position) |
Filing History |
| 2022-08-15 5:47 pm Purchase |
2022-08-11 | 13G | AnaptysBio, Inc. ANAB |
Flynn James E | 1,466,600 5.190% |
654,116 (+80.51%) |
Filing History |
| 2022-07-05 5:15 pm Purchase |
2022-06-30 | 13D | Acutus Medical, Inc. AFIB |
Flynn James E | 9,644,965 9.400% |
3,780,451 (+64.46%) |
Filing History |
| 2022-06-17 08:00 am Purchase |
2022-06-13 | 13G | Cogent Biosciences, Inc. COGT |
Flynn James E | 5,876,805 9.640% |
5,876,805 (New Position) |
Filing History |
| 2022-06-06 4:53 pm Purchase |
2022-05-25 | 13G | Evolus, Inc. EOLS |
Flynn James E | 3,030,299 5.410% |
3,030,299 (New Position) |
Filing History |